TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Magnetic Resonance Imaging/Spectroscopy Techniques

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~* All patients undergoing MRI in the Clinical Center.~* Patients must be able to provide informed consents.~EXCLUSION CRITERIA:~* Contraindications to MRI.~* Inability to understand consent form or consent process and the absence of a suitable guardian.~* Adults who are or may not be able to consent~* Patients in whom the scan must be performed quickly, i.e. those patients under anesthesia, anxious patients, those requiring emergency medical care, or others in which it is deemed inappropriate to prolong a study.~* Refusal to Participate.~* Pregnant women and fetuses~* Neonates

- Gender: ALL
- Minimum Age: None
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Patients undergoing MRI in the Clinical Center (Type: None): All patients who, by virtue of the NIH protocol in which they are enrolled, who qualify for MRI will be eligible for participation in this protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~I (first step):~* Admission to hospital~* Male or non-pregnant female, ≥60 years of age or ≥30 years of age plus one or more known risk factors (arterial hypertension, diabetes mellitus, coronary heart disease, heart failure, pre-existing chronic pulmonary disease)~* Confirmed SARS-CoV infection~* Radiographic evidence compatible with Covid-19 pneumonia (X-ray/CT scan, etc.)~* Signed Informed Consent Form~II (second step; indication for intervention):~* CRP ≥50mg/L plus 3 out of the following 5 criteria need to be fulfilled:~* Respiration Rate ≥25~* SpO2 \<93% (on ambient air)~* PaO2 \<65 mmHg~* Persistent or increasing dyspnoea as defined by a one point increase on the mMRC dyspnoea scale (over 1 hour)~* Persistent or increasing oxygen demand (over 1 hour)~Exclusion Criteria:~I (first step):~* Patients \>80 years of age~* Patient included in any other interventional trial~* Indication for imminent or immediate transfer to ICU~* Treatment with TCZ (or other anti-IL-6R treatment) within 4 weeks prior to baseline~* Uncontrolled bacterial superinfection according to investigator~* History of severe allergic reaction to TCZ~* History of diverticulitis requiring antibiotic treatment or history of colon perforation~* History of primary immunodeficiency (e.g. CVID) or progressing malignancy~* History of chronic liver disease (\>Child-Pugh A, or according to investigator)~II (second step; contraindication for intervention):~* Alanine transaminase/aspartate transaminase (ALT/AST) \>5 times of the upper limit of normal~* Hemoglobin \<80 g/L~* Leukocytes \<2.0 G/L~* Absolute neutrophil count \<1.0 G/L~* Platelets \<50 G/L

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Actemra (Type: EXPERIMENTAL): Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Digital Imaging Aid for Assessment of Cervical Dysplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years or older who are referred to the University of Texas MD Anderson Cancer Center Colposcopy Clinic for colposcopy are eligible for this study.~* Patients must sign an informed consent indicating awareness of the investigational nature of this study.~Exclusion Criteria:~* Patients who are pregnant are not eligible for this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Digital Imaging Device (Type: None): Patients with a diagnosis of cervical dysplasia that are scheduled for a colposcopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IBAT Inhibitor A4250 for Cholestatic Pruritus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria:~* Diagnosis of PBC or PBC-Autoimmune hepatitis overlap as established according to American Association for the Study of Liver Diseases/European Association for the Study of Liver (AASLD/EASL) definitions. Definite or probable PBC diagnosis, as demonstrated by the presence of ≥ 2 of the following 3 diagnostic factors:~* History of elevated alkaline phosphatase (ALP) levels (\>1.67 ULN) for at least 6 months prior to Day 1~* Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low titer (\<1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components (PDC-E2, 2-oxo-glutaric acid dehydrogenase complex)~* Liver biopsy consistent with PBC;~* Ursodeoxycholic acid (UDCA) non-responders defined as \>6 months of UDCA and at the time of enrolment a serum ALP \>1.67 ULN;~* Laboratory markers of cholestasis identified within 3 months of Visit 1;~* Treatment with cholestyramine at a dose \>4g BID or colestipol \> 5mg for at least 3 months;~* The patient has a VAS-Itch of at least 30 mm during the day before baseline (Visit 2);~* The patient is a male or non-pregnant female ≥18 years of age and ≤80 years of age with body mass index (BMI) ≥18.5 but \<35 kg/m2;~Major Exclusion Criteria:~* Any condition that, in the opinion of the Investigator constitutes a risk for the patient or a contraindication for participation and completion of the study, or could interfere with study objectives, conduct, or evaluations;~* Jaundice of extrahepatic origin;~* The patient has a structural abnormality of the GI tract;~* The patient has a known, active, clinically significant acute or chronic infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti infectives within 4 weeks of treatment start (study day 1) or completion of oral anti-infective treatment within 2 weeks prior to start of screening period;~* The patient has unexplained and clinically significant GI alarm signals (e.g., lower GI bleeding or heme-positive stool, iron-deficiency anaemia, unexplained weight loss) or systemic signs of infection or colitis;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A4250 (Type: EXPERIMENTAL): A4250 once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a competent, adult caregiver(s) who is able to recognize and observe the subject's seizure cluster episodes~2. Has an established diagnosis of partial or generalized epilepsy that includes all the following:~   * A documented history of seizure clusters lasting a minimum of 10 minutes, seizure cluster pattern is observable, stereotyped, and recognizably different from the subject's other non-cluster seizure activity (if any)~  * A second seizure in the seizure cluster typically occurs within 6 hours from the time of recognition~  * A seizure cluster pattern composed of multiple (≥ 2) partial or generalized seizures~  * A seizure cluster pattern established \>3 months before Visit 1~  * A frequency of ≥ 3 stereotyped seizure clusters during the year before Visit 1~  * At least 1 stereotyped seizure cluster occuring ≤ 4 months before Visit 1~3. Currently on a stable regimen of AED(s) that includes a benzodiazepine~4. Weight is 40 kg to 125 kg, inclusive~Exclusion Criteria:~1. Has a neurological disorder that is likely to progress in the next year~2. Has a severe chronic cardio-respiratory disease~3. Has a psychogenic, non-epileptic seizure(s) within the 5 years before Visit 1~4. Has a history of their stereotypical seizure cluster progressing to status epilepticus within 2 years before Visit 1~5. Has a history of acute narrow-angle glaucoma~6. Has had active suicidal plan/intent or active suicidal thoughts in the 6 months before Visit 1 or a suicide attempt in the past 5 years

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- USL261 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Systematic Search for Primary Immunodeficiency in Adults With Infections

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 yrs old patients~* ≥ 2 bacterial upper or lower respiratory tract infections/years, for at least 2 years, or~* ≥ 1 severe bacterial upper or lower respiratory tract infection requiring hospitalization and IV antibiotics, or~* ≥ 1 invasive infection (meningitis, bacteriemia, arthritis) due to Streptococcus pneumoniae, group A Streptococcus, Haemophilus influenzae, Neisseria meningitidis or Neisseria gonorrhoeae~Exclusion Criteria:~* concomitant, systemic comorbidity that predisposes to infection (solid or hematological cancer, diabetes mellitus, severe alcohol or intravenous drug abuse, chronic liver or kidney failure, human immunodeficiency virus infection, anatomic or functional asplenia, drug-induced 1 neutropenia, or solid organ or hematopoietic stem cell transplantation).~* the presence of a local predisposing factor: cigarette smoking (\> 5 pack-year and/or 5 cigarettes/day), underlying infection (tuberculosis, influenza...), chronic obstructive pulmonary disease, cystic fibrosis or bronchiectasis for pulmonary infections; cerebrospinal leak or preceding upper respiratory tract (URT) infections for non-meningococcal meningitis; oral, dental or skin condition for GAS infections~* use of corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressants or cytotoxic chemotherapeutics~* PID diagnosed before the infectious episode in question.~* current or recent pregnancy~* hospital-acquired infection (including infections of prostheses).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients with bacterial infections (Type: OTHER): Patients with recurrent and/or severe bacterial infections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Spitex-SpiTal-Autonomie-Reha-Kraft

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Community-dwelling prior to the hip fracture event~* Living alone or with a partner/family member~* Living in the city of Zurich~* age 70+~* Acute hip or pelvis fracture after minimal trauma (resulting from a fall occurring from a standard height and without the involvement of others or a vehicle)~* Living at home without or with minimal (i.e. no more than 1x/day) support from the Spitex (ambulant nursing service) before the hip fracture~* Participant is mentally competent (judicious) based on the treating physicians' opinion at the screening visit.~* Inpatient rehabilitation or inpatient transitional care at a nursing home or ambulatory standard of care~* The participant understands the study procedures and voluntarily agree to participate in the study and comply with all its procedures by giving written informed consent~Exclusion Criteria:~* Patients who are expected to return home without help (i.e. no more care than Spitex 1x/day or physiotherapy 2x/week needed) directly after acute care are excluded.~* Conservative treatment of acute hip fracture or surgical treatment that does not allow full weight bearing after surgery~* Currently under cancer treatment or has active cancer (except for non-melanoma skin cancer)~* Major visual or hearing impairment (visual and/or hearing aids are allowed) or other serious illness that would preclude participation~* 24-hour nursing care need as this cannot be offered within the STARK package~* Mobility impairment that precludes return to own apartment~* Planned nursing home admission after acute hospital stay~* Current participation in another clinical trial, or plans of such participation in the next 12 months (corresponding to the study duration)~* Inability to read and/or speak German to an extent necessary to understand instructions and participate in the study~* Unwilling to forego any additional vitamin D supplementation (bolus or regular intake).

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STARK intervention (Type: ACTIVE_COMPARATOR): New care concept for hip fracture patients
- Standard Care (Type: OTHER): Swiss standard of care for hip fracture patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Baseline ejection fraction ≥ 25% and ≤45% (as assessed by the site)~* NYHA class II or III (chronic, not transient, heart failure) despite receiving optimal medical therapy for heart failure~* Stable medication for heart failure for at least 30 days based on patient's medical records~* Baseline Peak VO2 ≥ 10 and ≤ 18.5 ml O2/Kg/min (as assessed by the site)~Exclusion Criteria:~* Potentially correctible cause of HF (valvular, congenital, or untreated ischemic heart disease)~* Clinically significant angina pectoris~* Hospitalization for HF requiring the use of inotropic support or IV diuretics within 30 days of enrollment~* PR interval greater than 375 ms~* Permanent or persistent atrial fibrillation/flutter or cardioversion within 30 days of enrollment.~* Exercise tolerance limited by condition other than heart failure (e.g., angina, chronic obstructive pulmonary disease (COPD), peripheral vascular disease, orthopedic or rheumatologic conditions) or unable to perform baseline stress testing~* Scheduled for a coronary artery bypass graft (CABG) or a percutaneous transluminal coronary angioplasty (PTCA) procedure, or CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment.~* Biventricular pacing system, or indication for Biventricular pacing system~* Myocardial infarction within 90 days of enrollment.~* Mechanical tricuspid or aortic valves.~* Ventricular assist device~* Prior heart transplant~* Pregnant or planning to become pregnant during the study~* Age below 18~* Subject participating in another study, unrelated to CCM, at the same time (or within 30 days prior to enrollment to this study)~* Subjects on dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device implant (Type: OTHER): Patients randomized to the treatment group will receive optimal medical therapy for heart failure. and implantation of the OPTIMIZER System.
- Optimal medical therapy (Type: ACTIVE_COMPARATOR): Patients randomized to the control group will receive optimal medical therapy for heart failure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Data Collection With the P200TE and P200TxE

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Male or female volunteers 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;~* Volunteers who can follow the instructions by the clinical staff at the clinical site;~* Volunteers who agree to participate;~* Volunteers who have been diagnosed with retina pathology with intra-retinal and/or subretinal fluid present in the posterior pole region.~Exclusion Criteria:~* Volunteers unable to tolerate ophthalmic imaging;~* Volunteers with ocular media not sufficiently clear to obtain acceptable OCT images.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- P200TxE Device First (Type: EXPERIMENTAL): None
- P200TE Device First (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cytokine Profiling Post-Heart Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Group 1~* 18 years and older~* Cardiac Transplant recipient with graft dysfunction of unknown etiology~Group 2~* 18 years or older~* No history of heart failure or cardiac transplantation Group 3~* 18 years or older~* Class II-IV heart failure Group 4~* 18 years or older~* Heart Transplant 6 months or greater prior to blood draw~* No graft dysfunction~Exclusion Criteria:~Group 1 Heart Transplant with Unexplained Graft Dysfunction~* Cellular or antibody-mediated cardiac allograft dysfunction~Group 2 Normal Control group~* Active infection within 1 month of blood draw~* Known Inflammatory Disease~Group 3 Heart Failure Group~* Active infection within 1 month of blood draw~* Known Inflammatory Disease~Group 4 Heart Transplant with Normal Graft Function Group~* Active infection within 1 month of blood draw~* Known graft dysfunction~* Known Inflammatory Disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: None): Heart Transplant Recipients with Unexplained Graft Dysfunction
- Group 2 (Type: None): Normal Control
- Group 3 (Type: None): Class III-IV Heart Failure
- Group 4 (Type: None): Heart Transplant Recipients with Normal Graft Function

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nurses Ability to Assess Visual Acuity in Geriatric Consultation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* at least 2 falls in the last 12 months,~* applied in geriatric evaluation~* talking French~* affiliated to the social security system~Exclusion Criteria:~* not communicating~* illiterate~* Total blindness

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues